GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
- Conditions
- Triple Negative Breast CancerPD-L1 Negative
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 540
- Registration Number
- NCT05382299
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, China
🇨🇳Deyang People's Hospital, Deyang, China
🇨🇳Sun Yat-Sen University Cancer Center, Guangzhou, China
Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 77
- Registration Number
- NCT05330429
- Locations
- 🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Virginia Cancer Specialists, PC, Arlington, Virginia, United States
🇺🇸Seattle Cancer Care Alliance (SCCA), Seattle, Washington, United States
Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT05281510
- Locations
- 🇿🇦
FRESH Clinical Research Site: Females Rising through Education, Support and Health, Umlazi, South Africa
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 193
- Registration Number
- NCT05186974
- Locations
- 🇭🇰
Queen Elizabeth Hospital, Hong Kong, Hong Kong
🇲🇾Institut Kanser Negara, Putrajaya, Malaysia
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT05165771
Study of Sacituzumab Govitecan in Patients With Solid Tumor
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT05119907
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, China
🇨🇳Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China
🇨🇳Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
- Conditions
- HR+/HER2- Metastatic Breast CancerMetastatic Urothelial CancerAdvanced Solid TumorMetastatic Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 143
- Registration Number
- NCT05101096
- Locations
- 🇯🇵
Kagawa University Hospital, Kagawa, Japan
🇯🇵Aichi Cancer Center Hospital, Aichi, Japan
🇯🇵Akita University Hospital, Akita, Japan
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Biological: Sacituzumab Govitecan-hziy (SG)
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 603
- Registration Number
- NCT05089734
- Locations
- 🇺🇸
Maryland Oncology Hematology, P.A., Clinton, Maryland, United States
🇺🇸W.G (Bill) Hefner VAMC, Salisbury, North Carolina, United States
🇺🇸Florida Cancer Specialists, West Palm Beach, Florida, United States
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 378
- Registration Number
- NCT05079230
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UC Irvine Health- Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸The University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 142
- Registration Number
- NCT05052996
- Locations
- 🇺🇸
Ruane Clinical Research Group, Inc, Los Angeles, California, United States
🇺🇸Mills Clinical Research, Los Angeles, California, United States
🇺🇸Emory University Hospital Midtown Infectious Disease Clinic, Atlanta, Georgia, United States